Synapse - Sujata Patil

Search Within

Sujata Patil

Results (511)

Quantitative apparent diffusion coefficient measurement obtained by 3.0 Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer

Journal Article

Durando, M.; Gennaro, L.; Cho, G. Y.; Giri, D. D.; Gnanasigamani, M. M.; Patil, S.; Sutton, E. J.; Deasy, J. O.; Morris, E. A.; Thakur, S. B.
European Journal of Radiology (2016)

Fulltext@MSK | Save

Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer

Meeting Abstract

McArthur, H. L.; Page, D.; Proverbs-Singh, T.; Solomon, S.; Hudis, C.; Norton, L.; Patil, S.; Barrett, J. A.; Lebel, F.
Cancer Research (2016)

Fulltext@MSK | Save

Androgen receptor (AR) mutations in a cohort of patients with breast cancer (BC) who have undergone tumor genomic profiling

Meeting Abstract

Gucalp, A.; Proverbs-Singh, T. A.; Razavi, P.; Chandarlapaty, S.; Patil, S.; Ross, D. S.; Zehir, A.; Baselga, J.; Hudis, C. A.; Traina, T. A.
Cancer Research (2016)

Fulltext@MSK | Save

Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience

Meeting Abstract

Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; more...
Cancer Research (2016)

Fulltext@MSK | Save

Optimization of intermittent high dose lapatinib administration with or without capecitabine: A rational approach to drug dosing and scheduling using Norton-Simon modeling

Meeting Abstract

Morikawa, A.; De Stanchina, E.; Patil, S.; Chandarlapaty, S.; Li, B. T.; Norton, L.; Seidman, A. D.
Cancer Research (2016)

Fulltext@MSK | Save

A phase 1/2 study of once-daily oral VT-464 in patients with advanced androgen receptor (AR) positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)

Meeting Abstract

Gucalp, A.; Hudis, C.; Norton, L.; Patil, S.; Kurman, M. R.; Eisner, J. R.; Moore, W. R.; Traina, T. A.
Cancer Research (2016)

Fulltext@MSK | Save

A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC)

Meeting Abstract

Jhaveri, K.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; Haque, S.; more...
Cancer Research (2016)

Fulltext@MSK | Save

Fertility preservation for the young breast cancer patient

Journal Article

Goldfarb, S. B.; Kamer, S. A.; Oppong, B. A.; Eaton, A.; Patil, S.; Junqueira, M. J.; Olcese, C.; Kelvin, J. F.; Gemignani, M. L.
Annals of Surgical Oncology (2016)

Fulltext@MSK | Save

Cardiac safety of paclitaxel plus trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer

Journal Article

Yu, A. F.; Manrique, C.; Pun, S.; Liu, J. E.; Mara, E.; Fleisher, M.; Patil, S.; Jones, L. W.; Steingart, R. M.; Hudis, C. A.; more...
The Oncologist (2016)

Fulltext@MSK | Save

Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status

Journal Article

Shah, P. D.; Patil, S.; Dickler, M. N.; Offit, K.; Hudis, C. A.; Robson, M. E.
Cancer (2016)

Fulltext@MSK | Save